Anthony Muratore has more than 35 years of experience in the area of intellectual property law and is consistently recognized as one of Australia's leading patent litigators. He has established a reputation acting as the Australian member of global teams representing clients in multijurisdictional patent disputes.
Anthony has acted in a range of matters involving biotechnology, pharmaceuticals, mechanical engineering, chemistry, and information technology. In the biotechnology and health care fields, he has acted in matters involving patents relating to drug formulation, transdermal drug delivery devices, synthetic nucleotides, sterility assurance, gene silencing, photodynamic therapy, contact lenses, and CPAP for the treatment of sleep apnea.
Some of these matters are amongst Australia's most high-profile cases that have tested and established some of the most fundamental aspects of Australian patent law. These include the High Court's rulings on whether isolated nucleic acids (Myriad Genetics) and methods of treatments of human beings (Sanofi v. Apotex) are patentable subject matter under Australian law.
Currently, Anthony acts for clients in patent disputes involving key technology and blockbuster pharmaceuticals. This includes acting for AbbVie in relation to Humira, Sanofi in relation to Praluent (PCSK9), and Toolgen Inc. in relation to revolutionary CRISPR gene editing technology.
Anthony is on the WIPO list of arbitrators and is a member and past chairman of the Intellectual Property Law subcommittee of the Law Council of Australia.
Federal Court of Australia Orders First Site-Blocking Injunctions to Reduce Online Copyright Infringement
- April 2018IP Rights Reform Is Price to Pay for Revamped Trans-Pacific Partnership Agreement
- June 2017Australian Court Approves Use of American 28 USC § 1782 for Assistance to Foreign Litigants
- April 2017Recovery of Damages Under Innovation Patents in Australia
- January 2017Federal Court of Australia Orders First Site-Blocking Injunctions to Reduce Online Copyright Infringement
- May 2016Australian Court Stops Class Action from Obtaining U.S. Courts' Assistance for Oral Depositions
- University of New South Wales (LL.B. and B.A. 1978)
- New South Wales
Consistently ranked in Best Lawyers in Australia for biotechnology law, IP law, and litigation
Consistently ranked as a top professional in the IAM Patent 1000 — The World's Leading Patent Practitioners
Ranked in Chambers Asia Pacific since 2014 for intellectual property
"Leading individual" in Chambers Global for intellectual property — patents — Australia
Consistently ranked as "preeminent" in Doyle's Guide — Leading Patent Litigation Lawyers — Australia